

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 1b trial

Lancet Oncology, The

15, 69-77

DOI: [10.1016/s1470-2045\(13\)70551-5](https://doi.org/10.1016/s1470-2045(13)70551-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 453.	0.6	0
2	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. Journal of Receptor, Ligand and Channel Research, 2014, , 1.	0.7	2
3	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and Personalized Medicine, 2014, 7, 357.	0.4	60
4	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
5	Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects. Expert Review of Hematology, 2014, 7, 671-681.	1.0	8
6	Pidilizumab in the treatment of diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy, 2014, 14, 1361-1368.	1.4	20
7	New antibody approaches to lymphoma therapy. Journal of Hematology and Oncology, 2014, 7, 58.	6.9	50
8	Anti-PD-1 antibodies for the treatment of B-cell lymphoma. OncoImmunology, 2014, 3, e28101.	2.1	5
9	Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer Journal, 2014, 4, e236-e236.	2.8	54
10	Overcoming tumor-mediated immunosuppression. Immunotherapy, 2014, 6, 973-988.	1.0	38
11	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. Frontiers in Oncology, 2014, 4, 351.	1.3	15
12	Therapeutic targeting of microenvironment in follicular lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 169-173.	0.9	5
13	Immune checkpoints in cancer clinical trials. Chinese Journal of Cancer, 2014, 33, 434-444.	4.9	96
14	Rush Hour Traffic: Directing T Cells to Tumor. Journal of the National Cancer Institute, 2014, 106, dju301-dju301.	3.0	0
15	Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies. Drugs, 2014, 74, 1993-2013.	4.9	96
16	Oncogene withdrawal engages the immune system to induce sustained cancer regression. , 2014, 2, 24.		19
17	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. Rambam Maimonides Medical Journal, 2014, 5, e0024.	0.4	11
18	Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology, 2014, 7, 481-493.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Epigenetics, opium, and cancer. <i>Lancet Oncology</i> , The, 2014, 15, e153.	5.1	6
20	Complications of prostate cancer treatment – Author's reply. <i>Lancet Oncology</i> , The, 2014, 15, e152-e153.	5.1	0
21	Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 700-713.	1.1	1,333
22	Double act in follicular lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 64-64.	12.5	0
23	Immune modulation for cancer therapy. <i>British Journal of Cancer</i> , 2014, 111, 2214-2219.	2.9	128
24	Response to Lankarani. <i>American Journal of Gastroenterology</i> , 2014, 109, 600-601.	0.2	2
25	Follicular helper T cells: expanding roles in T cell lymphoma and targets for treatment. <i>British Journal of Haematology</i> , 2014, 166, 326-335.	1.2	49
26	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	3.2	17
27	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. <i>International Journal of Cancer</i> , 2014, 135, 2834-2846.	2.3	31
28	The tumour microenvironment in B cell lymphomas. <i>Nature Reviews Cancer</i> , 2014, 14, 517-534.	12.8	417
29	Rituximab in follicular lymphoma: the first chapter of the new era?. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 267-273.	0.7	0
30	CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. <i>Blood</i> , 2015, 125, 2381-2385.	0.6	61
31	Molecular Biomarkers in Gastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e19-e29.	2.3	30
32	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29325.	3.6	51
33	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 247.	1.8	57
34	Update on checkpoint blockade therapy for lymphoma. , 2015, 3, 33.		11
35	Genomic alterations underlying immune privilege in malignant lymphomas. <i>Current Opinion in Hematology</i> , 2015, 22, 343-354.	1.2	18
36	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. <i>Current Opinion in Oncology</i> , 2015, 27, 384-391.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Targeting immune checkpoints in lymphoma. <i>Current Opinion in Hematology</i> , 2015, 22, 337-342.	1.2	38
38	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	0.9	17
39	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. <i>Aids</i> , 2015, 29, 1911-1915.	1.0	14
40	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	3.9	1,112
41	Lymphoma: Immune Evasion Strategies. <i>Cancers</i> , 2015, 7, 736-762.	1.7	35
42	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. <i>Karger Kompass Onkologie</i> , 2015, 2, 8-14.	0.0	0
43	Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. <i>Pharmaceuticals</i> , 2015, 8, 607-636.	1.7	15
44	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. <i>Frontiers in Immunology</i> , 2015, 6, 258.	2.2	16
45	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015, 6, 448.	2.2	36
46	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
47	PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. <i>PLoS ONE</i> , 2015, 10, e0136476.	1.1	59
48	Clinical Development of Immune Checkpoint Inhibitors. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	51
49	Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	17
50	Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3113-3120.	3.2	109
51	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. <i>Current Oncology Reports</i> , 2015, 17, 27.	1.8	3
52	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1545-1552.	0.8	73
53	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. <i>Current Oncology Reports</i> , 2015, 17, 30.	1.8	9
54	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 764-782.	1.1	469

#	ARTICLE	IF	CITATIONS
55	Immune Checkpoint Modulation for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2256-2262.	3.2	90
56	Checkpoint blockade in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 69-73.	0.9	11
57	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <i>Cancer Cell</i> , 2015, 28, 690-714.	7.7	1,205
58	The use of combinations of monoclonal antibodies in clinical oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 859-867.	3.4	79
59	Current status of checkpoint inhibitors in lymphoma. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 167-174.	0.7	0
61	Checkpoint inhibitors in immunotherapy of ovarian cancer. <i>Tumor Biology</i> , 2015, 36, 33-39.	0.8	19
62	Chemotherapy-free treatment in patients with follicular lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 187-203.	1.0	8
63	New therapies in non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 349-359.	1.1	5
65	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	0.8	2,220
66	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
67	Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. <i>Current Opinion in Immunology</i> , 2015, 33, 1-8.	2.4	24
69	Advances in the treatment of follicular lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 207-218.	0.5	0
70	The effect of ionizing radiation on regulatory T cells in health and disease. <i>Cancer Letters</i> , 2015, 368, 252-261.	3.2	90
71	Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 409-415.e1.	0.2	21
72	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncology</i> , 2015, 4, e1008814.	2.1	102
73	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. <i>Drug Discovery Today</i> , 2015, 20, 1127-1134.	3.2	27
74	Emerging immunological drugs for chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 423-447.	1.0	9
75	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	1.9	41

#	ARTICLE	IF	CITATIONS
76	Immune Modulation in Hematologic Malignancies. <i>Seminars in Oncology</i> , 2015, 42, 617-625.	0.8	22
77	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015, 21, 3853-3861.	3.2	20
78	Report on the 56th ASH Annual Meeting, San Francisco,. <i>Ecancermedalscience</i> , 2015, 9, 514.	0.6	3
79	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	1.0	136
80	Anti-PD-1-Targeted Therapies Focusing on Lymphatic Malignancies: Biological Rationale, Clinical Challenges and Opportunities. <i>Acta Haematologica</i> , 2015, 133, 129-135.	0.7	8
81	Immuno-regulatory antibodies for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 787-801.	1.4	40
82	Programmed cell death-1 inhibition in lymphoma. <i>Lancet Oncology</i> , The, 2015, 16, e234-e245.	5.1	56
84	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	4.9	18
85	Current Therapeutic Strategies and New Treatment Paradigms for Follicular Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 197-226.	0.2	9
86	Immune checkpoint blockade in hematologic malignancies. <i>Blood</i> , 2015, 125, 3393-3400.	0.6	208
87	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 897-912.	1.9	12
88	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	5.8	134
89	Haematological malignancies: at the forefront of immunotherapeutic innovation. <i>Nature Reviews Cancer</i> , 2015, 15, 201-215.	12.8	63
90	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. <i>Molecular Immunology</i> , 2015, 67, 4-17.	1.0	180
91	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. <i>Future Oncology</i> , 2015, 11, 1327-1342.	1.1	61
92	PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 203-211.	0.6	158
93	⁸⁹ Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies. <i>Radiology</i> , 2015, 275, 490-500.	3.6	121
94	Immune checkpoint inhibition in lymphoid disease. <i>British Journal of Haematology</i> , 2015, 170, 291-304.	1.2	20

#	ARTICLE	IF	CITATIONS
95	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 25-36.	1.1	13
96	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2015, 13, 265-272.	1.9	188
97	Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1507-1518.	1.0	44
98	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015, 26, 2375-2391.	0.6	1,136
99	Regulatory B cells in anti-tumor immunity. <i>International Immunology</i> , 2015, 27, 521-530.	1.8	119
101	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.	2.1	87
102	Several immune escape patterns in non-Hodgkin's lymphomas. <i>Oncolimmunology</i> , 2015, 4, e1026530.	2.1	82
103	Injectable cryogel-based whole-cell cancer vaccines. <i>Nature Communications</i> , 2015, 6, 7556.	5.8	312
104	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. <i>Oncolimmunology</i> , 2015, 4, e1026503.	2.1	33
105	Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1337-1349.	1.1	5
106	Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. <i>Oncolimmunology</i> , 2015, 4, e1008853.	2.1	12
107	Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 2471-2484.	1.1	70
108	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. <i>Immunotherapy</i> , 2015, 7, 1169-1186.	1.0	45
109	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2015, 7, 1213-1227.	1.0	77
110	PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 215-221.	3.3	24
111	Clinical blockade of PD1 and LAG3 – potential mechanisms of action. <i>Nature Reviews Immunology</i> , 2015, 15, 45-56.	10.6	524
112	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 311-319.	13.9	3,099
113	Radiotherapy and Toll-Like Receptor Agonists. <i>Seminars in Radiation Oncology</i> , 2015, 25, 34-39.	1.0	24

#	ARTICLE	IF	CITATIONS
114	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015, 21, 24-33.	3.5	628
115	Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2239-2250.	0.6	18
116	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology, 2015, 27, 39-46.	1.8	286
117	Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. Blood Reviews, 2015, 29, 25-32.	2.8	38
118	19. Translating science into therapy of lymphoma. , 2016, , 379-402.		0
119	THE ROLE OF ALITOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, e2016045.	0.5	4
120	NOVEL DRUGS IN FOLLICULAR LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016061.	0.5	12
121	PD1 blockade enhances cytotoxicity of <i>in vitro</i> expanded natural killer cells towards myeloma cells. Oncotarget, 2016, 7, 48360-48374.	0.8	57
122	Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches. Frontiers in Immunology, 2016, 7, 152.	2.2	80
123	Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies. Frontiers in Immunology, 2016, 7, 492.	2.2	39
124	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	2.2	409
125	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 2016, 17, 1151.	1.8	134
126	Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies. Journal of Translational Medicine, 2016, 14, 252.	1.8	3
127	PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, 2016, Volume 9, 5023-5039.	1.0	558
128	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget, 2016, 7, 73068-73079.	0.8	76
129	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy, 2016, 8, 809-819.	1.0	44
130	Novel Immunotherapies for B-Cell Lymphomas and Leukemias. American Journal of Therapeutics, 2016, 23, e1157-e1181.	0.5	3
131	Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. British Journal of Haematology, 2016, 173, 597-616.	1.2	16

#	ARTICLE	IF	CITATIONS
132	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2016, 175, 102-114.	1.2	56
133	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , 2016, 68, 1079-1089.	1.6	135
134	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolimmunology</i> , 2016, 5, e1186323.	2.1	2
137	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. , 2016, 4, 95.		18
138	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
139	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. <i>Immunotherapy</i> , 2016, 8, 1335-1346.	1.0	9
140	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
141	Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 277-283.	0.9	7
142	Novel agents in follicular lymphoma: choosing the best target. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 284-292.	0.9	3
143	Checkpoint inhibition and cellular immunotherapy in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 390-396.	0.9	8
144	T Follicular Helper Cells in Transplantation. <i>Transplantation</i> , 2016, 100, 1650-1655.	0.5	58
145	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. <i>Melanoma Research</i> , 2016, 26, 469-480.	0.6	30
147	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 31.	1.3	57
148	Inhibitory immunologiczných punktů w kontrolnych podziałach komórki w leczeniu chorób nowotworowych. <i>Acta Haematologica Polonica</i> , 2016, 47, 155-162.	0.1	1
149	The Expanding Spectrum of Follicular Lymphoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 29-40.	0.7	3
150	Novel therapies under investigation for mantle cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 375-380.	1.9	2
151	Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 29-36.	1.2	23
152	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1269-1280.	0.6	4

#	ARTICLE	IF	CITATIONS
153	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 989-1004.	1.4	10
154	Programming the immune checkpoint to treat hematologic malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 755-770.	1.9	11
155	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. <i>Drug Discovery Today</i> , 2016, 21, 1027-1036.	3.2	137
156	Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?. <i>Journal of Oncology Practice</i> , 2016, 12, 101-106.	2.5	12
157	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
158	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
159	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 665-674.	1.0	39
160	Is watch and wait still acceptable for patients with low-grade follicular lymphoma?. <i>Blood</i> , 2016, 127, 2804-2808.	0.6	30
161	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R469-R484.	1.6	12
162	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 581-590.	1.4	71
163	Speed bumps on the road to a chemotherapy-free world for lymphoma patients. <i>Blood</i> , 2016, 128, 325-330.	0.6	17
164	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016, 101, 1144-1158.	1.7	6
165	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	7.1	36
166	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. <i>Haematologica</i> , 2016, 101, 976-984.	1.7	70
167	PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. <i>Immunotherapy</i> , 2016, 8, 1081-1089.	1.0	32
169	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
170	Impaired functional responses in follicular lymphoma CD8 ⁺ TIM-3 ⁺ T lymphocytes following TCR engagement. <i>Oncolmmunology</i> , 2016, 5, e1224044.	2.1	32
171	Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1033-1045.	2.5	1

#	ARTICLE	IF	CITATIONS
172	New drugs for follicular lymphoma. <i>Leukemia Research</i> , 2016, 49, 38-46.	0.4	3
173	Targeting natural killer cells in cancer immunotherapy. <i>Nature Immunology</i> , 2016, 17, 1025-1036.	7.0	865
174	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	0.6	370
175	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. <i>Expert Review of Hematology</i> , 2016, 9, 939-949.	1.0	13
176	B cell regulation of the anti-tumor response and role in carcinogenesis. , 2016, 4, 40.		189
177	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016, 8, 328rv4.	5.8	1,844
178	Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 1-19.	0.3	39
179	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2016, 28, e127-e138.	0.6	35
180	Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. <i>Oncot Immunology</i> , 2016, 5, e1188246.	2.1	43
181	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	7.7	785
182	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
183	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
184	Breakthrough therapies in B-cell non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2016, 27, 778-787.	0.6	38
185	Current status of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 191-203.	0.6	52
186	Targeting B-cell non Hodgkin lymphoma: New and old tricks. <i>Leukemia Research</i> , 2016, 42, 93-104.	0.4	51
187	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 413-425.	1.1	115
188	Immune checkpoint blockade in lymphoid malignancies. <i>FEBS Journal</i> , 2016, 283, 2233-2244.	2.2	18
189	Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treatment Reviews</i> , 2016, 44, 51-60.	3.4	706

#	ARTICLE	IF	CITATIONS
190	Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. Expert Review of Clinical Immunology, 2016, 12, 673-679.	1.3	6
191	Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, S9-S14.	2.0	0
192	Immunotherapy of Cancer. , 2016, , .		3
193	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 101, 75-85.	2.0	105
194	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
195	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Annals of Oncology, 2016, 27, 397-408.	0.6	37
196	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Therapeutic Advances in Respiratory Disease, 2016, 10, 183-193.	1.0	112
197	The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a G1TR Agonist Monoclonal Antibody in Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 574-586.	1.3	15
198	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Reviews, 2016, 30, 189-200.	2.8	34
199	Treatment of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy. Medical Hypotheses, 2016, 86, 129-131.	0.8	2
200	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. Expert Review of Hematology, 2016, 9, 123-135.	1.0	2
201	Novel immunotherapies in lymphoid malignancies. Nature Reviews Clinical Oncology, 2016, 13, 25-40.	12.5	224
202	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, 17-22.	2.0	16
203	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 58-71.	3.3	49
204	The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies. International Reviews of Immunology, 2016, 35, 136-155.	1.5	3
205	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Critical Reviews in Oncology/Hematology, 2016, 97, 65-71.	2.0	30
206	The IL-15-Based ALT-803 Complex Enhances Fcγ3R111a-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas. Clinical Cancer Research, 2016, 22, 596-608.	3.2	130
207	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. Journal of Leukocyte Biology, 2016, 99, 87-96.	1.5	73

#	ARTICLE	IF	CITATIONS
208	Treatment approaches of hard-to-treat non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2017, 10, 259-273.	1.0	9
209	Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2017, 96, 919-927.	0.8	20
210	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. <i>Cell Communication and Signaling</i> , 2017, 15, 1.	2.7	154
211	Immunoprofiling as a predictor of patient's response to cancer therapy" promises and challenges. <i>Current Opinion in Immunology</i> , 2017, 45, 60-72.	2.4	39
212	Emerging role of checkpoint blockade therapy in lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 81-90.	1.1	32
213	Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 717-729.	2.0	41
214	Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 627-636.	2.0	133
215	Targeting the programmed death-1 pathway in lymphoid neoplasms. <i>Cancer Treatment Reviews</i> , 2017, 54, 99-109.	3.4	27
216	<scp>TAM</scp> receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. <i>Immunological Reviews</i> , 2017, 276, 165-177.	2.8	125
217	Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. <i>International Journal of Cancer</i> , 2017, 141, 1018-1028.	2.3	116
218	Targeting indolent non-Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 299-313.	1.0	4
219	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	0.6	335
220	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 851-861.	1.2	82
221	Novel Insights into Membrane Targeting of B Cell Lymphoma. <i>Trends in Cancer</i> , 2017, 3, 442-453.	3.8	19
222	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2017, 96, e6398.	0.4	43
223	Management of Lymphomas: A Case-Based Approach. , 2017, , .		0
224	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
225	Checkpoint Blockade Immunotherapy for Glioblastoma. , 2017, , 261-300.		2

#	ARTICLE	IF	CITATIONS
226	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <i>Neuro-Oncology</i> , 2017, 19, 1047-1057.	0.6	325
227	Follicular lymphoma: State of the art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	0.8	11
228	Antibody-Based Cancer Therapy. <i>International Review of Cell and Molecular Biology</i> , 2017, 331, 289-383.	1.6	41
229	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	1.8	27
230	New targeted therapies for malignant lymphoma based on molecular heterogeneity. <i>Expert Review of Hematology</i> , 2017, 10, 39-51.	1.0	14
231	The emerging role of immune checkpoint inhibition in malignant lymphoma. <i>Haematologica</i> , 2017, 102, 30-42.	1.7	101
232	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 335-346.	12.5	56
233	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2017, 29, 218-230.	0.6	49
234	Checkpoint Inhibition in Non-Hodgkin's Lymphoma. <i>Oncology Research and Treatment</i> , 2017, 40, 662-672.	0.8	4
235	Current challenges in the management of follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 13-24.	0.7	1
236	Immune checkpoint inhibitor-associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new entity of drug-induced autoimmune encephalitis?. <i>European Journal of Cancer</i> , 2017, 87, 205-208.	1.3	15
238	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 484-494.	1.2	4
239	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolimmunology</i> , 2017, 6, e1373237.	2.1	62
240	Roles for Innate Immunity in Combination Immunotherapies. <i>Cancer Research</i> , 2017, 77, 5215-5221.	0.4	81
241	An Update on the Use of Immunotherapy in the Treatment of Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 282-289.	1.2	1
242	PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. <i>Immunology</i> , 2017, 152, 357-371.	2.0	108
243	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186
244	PD-1/PD-L1 as a prognostic factor in leukemia. <i>Journal of Hematopathology</i> , 2017, 10, 17-24.	0.2	17

#	ARTICLE	IF	CITATIONS
245	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358
247	Immunotherapy in Waldenström's Macroglobulinemia. , 2017, , 315-326.		0
248	The evolving role of targeted biological agents in the management of indolent B-cell lymphomas. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 329-344.	1.1	4
249	Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. <i>Chinese Journal of Cancer</i> , 2017, 36, 94.	4.9	47
250	Hematopoietic cell transplants for Hodgkin lymphoma. , 0, , 361-371.		0
251	Hematopoietic cell transplants for chronic lymphocytic leukemia: Changing landscape?. , 0, , 372-383.		0
253	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <i>Blood Advances</i> , 2017, 1, 1884-1890.	2.5	40
254	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 49.	1.6	459
255	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1259-1271.	0.9	16
256	Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 2643-2654.	2.5	91
257	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2349-2363.	1.0	35
258	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2017, 8, 561.	1.6	1,276
259	Role of Natural Killer Cells in HIV-Associated Malignancies. <i>Frontiers in Immunology</i> , 2017, 8, 315.	2.2	5
260	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. <i>Frontiers in Immunology</i> , 2017, 8, 1245.	2.2	124
261	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. <i>Frontiers in Immunology</i> , 2017, 8, 1804.	2.2	54
262	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 52889-52900.	0.8	82
263	Incorporation of functional elements enhances the antitumor capacity of CAR T cells. <i>Experimental Hematology and Oncology</i> , 2017, 6, 28.	2.0	22
264	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2851-2860.	2.0	34

#	ARTICLE	IF	CITATIONS
265	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <i>Oncotarget</i> , 2017, 8, 44960-44975.	0.8	82
266	Immune checkpoints, their control by immunotherapy and ovarian cancer. <i>Wspolczesna Onkologia</i> , 2017, 3, 189-196.	0.7	2
267	The clinical development of obinutuzumab for the treatment of follicular lymphoma. <i>Cancer Management and Research</i> , 2017, Volume 9, 103-113.	0.9	4
268	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	0.8	298
269	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. <i>Oncotarget</i> , 2017, 8, 41932-41946.	0.8	95
270	The role of novel immunotherapies in non-Hodgkin lymphoma. <i>Translational Cancer Research</i> , 2017, 6, 93-103.	0.4	26
271	Immune checkpoint blockade for hematologic malignancies: a review. <i>Stem Cell Investigation</i> , 2017, 4, 32-32.	1.3	59
272	A Diversity of Cancer Incidence and Mortality in West Asian Populations. <i>Annals of Global Health</i> , 2018, 80, 346.	0.8	44
273	Rituximab as a therapeutic option for patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 917-924.	2.0	22
274	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1094-1105.	3.3	164
275	Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. <i>Journal of Controlled Release</i> , 2018, 274, 24-34.	4.8	123
276	PD-1 /PD-L1 checkpoint in hematological malignancies. <i>Leukemia Research</i> , 2018, 67, 45-55.	0.4	33
277	Checkpoint-Inhibition bei Non-Hodgkin-Lymphom. <i>Karger Kompass Onkologie</i> , 2018, 5, 12-20.	0.0	0
278	Checkpoint molecule expression by B and T cell lymphomas in dogs. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 352-360.	0.8	25
279	Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma. <i>Nanomedicine</i> , 2018, 13, 297-311.	1.7	4
280	Current Status of Immuno-Oncology in Hematologic Cancers. , 2018, , 641-655.		0
281	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. <i>Annals of Oncology</i> , 2018, 29, 332-340.	0.6	20
282	Monoclonal Antibodies Targeting Hematological Malignancies. , 2018, , 79-116.		0

#	ARTICLE	IF	CITATIONS
283	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	6.9	256
284	Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. <i>Oncology</i> , 2018, 94, 259-273.	0.9	15
285	Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery. <i>OncolImmunology</i> , 2018, 7, e1448330.	2.1	24
286	Immunology of the Lymphomas. , 2018, , 827-852.		1
287	PD-1 and cancer: molecular mechanisms and polymorphisms. <i>Immunogenetics</i> , 2018, 70, 73-86.	1.2	100
288	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	0.6	90
289	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. <i>OncolImmunology</i> , 2018, 7, e1386826.	2.1	26
290	The application and mechanism of PD pathway blockade for cancer therapy. <i>Postgraduate Medical Journal</i> , 2018, 94, 53-60.	0.9	10
291	Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. <i>European Journal of Internal Medicine</i> , 2018, 47, 6-13.	1.0	52
292	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
293	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 870-881.	3.2	75
294	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 393-398.	0.5	230
295	Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 189-195.	1.4	33
296	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. <i>Blood</i> , 2018, 131, 68-83.	0.6	311
297	Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment. <i>Leukemia and Lymphoma</i> , 2018, 59, 1064-1072.	0.6	18
298	Strategies to enhance NK cell function for the treatment of tumors and infections. <i>Critical Reviews in Immunology</i> , 2018, 38, 105-130.	1.0	25
299	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 400-414.	1.8	63
300	Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. <i>IScience</i> , 2018, 9, 258-277.	1.9	83

#	ARTICLE	IF	CITATIONS
301	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
302	Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1231-1239.	1.1	18
303	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. <i>Seminars in Oncology</i> , 2018, 45, 291-302.	0.8	37
304	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6505-6524.	1.0	47
305	Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 543-554.	1.2	31
306	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
307	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT). <i>American Journal of Surgical Pathology</i> , 2018, 42, 843-854.	2.1	54
308	Blockade of the Checkpoint Inhibitor Pathways and Activated T-Cell Therapy in Brain Tumors. , 2018, , 669-680.		0
309	Immune Checkpoint Blockade in Hematologic Malignancies. , 2018, , 1583-1587.		1
310	Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. <i>Frontiers in Immunology</i> , 2017, 8, 1936.	2.2	39
311	Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. <i>Frontiers in Immunology</i> , 2018, 9, 416.	2.2	91
312	Centrin-Deleted <i>Leishmania donovani</i> Parasites Help CD4+ T Cells to Acquire Th1 Phenotype and Multi-Functionality Through Downregulation of CD200â€œCD200R Immune Inhibitory Axis. <i>Frontiers in Immunology</i> , 2018, 9, 1176.	2.2	11
313	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
314	Cancer Immunotherapy and the Immune Response in Follicular Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 219.	1.3	11
315	Bendamustine and rituximab in elderly patients with lowâ€œtumour burden follicular lymphoma. Results of the <sc>LYSA</sc> phase <sc>II BRIEF</sc> study. <i>British Journal of Haematology</i> , 2018, 183, 76-86.	1.2	14
316	Renewed interest for lowâ€œdose radiation therapy in follicular lymphomas: From biology to clinical applications. <i>Hematological Oncology</i> , 2018, 36, 723-732.	0.8	3
317	Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. <i>Molecular Pharmaceutics</i> , 2018, 15, 4426-4433.	2.3	37
318	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. <i>Current Medicinal Chemistry</i> , 2018, 25, 1327-1339.	1.2	99

#	ARTICLE	IF	CITATIONS
319	Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 497-509.	1.4	8
320	Natural killer cellâ€‘based immunotherapy: From transplantation toward targeting cancer stem cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 259-273.	2.0	43
321	Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study. <i>Surgical and Experimental Pathology</i> , 2019, 2, .	0.2	1
322	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	1.9	36
323	Noncellular Immune Therapies for Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 707-725.	0.9	7
324	NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. <i>Annals of Translational Medicine</i> , 2019, 7, 105-105.	0.7	143
325	Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	0
326	Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. <i>International Immunopharmacology</i> , 2019, 77, 105999.	1.7	43
327	PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance. <i>Molecules</i> , 2019, 24, 3784.	1.7	26
328	Natural killer cells: a review of biology, therapeutic potential and challenges in treatment of solid tumors. <i>Future Oncology</i> , 2019, 15, 3053-3069.	1.1	34
329	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4315.	1.8	21
330	Lymphomas and Their Microenvironment: A Multifaceted Relationship. <i>Pathobiology</i> , 2019, 86, 225-236.	1.9	20
331	Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 134.	1.0	6
332	Programmed cell death protein receptor and ligands in haematological malignancies â€‘ Current status. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 47-58.	2.0	4
333	Recent advances in the clinical development of immune checkpoint blockade therapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 609-626.	2.1	76
334	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <i>Frontiers in Oncology</i> , 2019, 9, 443.	1.3	25
335	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	1.8	13
336	Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. <i>SLAS Technology</i> , 2019, 24, 457-476.	1.0	8

#	ARTICLE	IF	CITATIONS
337	Principles of Immunotherapy. , 2019, , 295-304.		0
338	Potential Use of Gluconate in Cancer Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 522.	1.3	22
339	Targeting immune cells for cancer therapy. <i>Redox Biology</i> , 2019, 25, 101174.	3.9	151
340	Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 454.	2.2	48
341	Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study. <i>Clinical and Translational Oncology</i> , 2019, 21, 1093-1103.	1.2	7
342	Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. <i>BioMed Research International</i> , 2019, 2019, 1-13.	0.9	5
343	Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer. <i>Nano Today</i> , 2019, 29, 100801.	6.2	48
344	Application of multiplexed pharmacokinetic immunoassay to quantify in vivo drug forms and coadministered biologics. <i>Bioanalysis</i> , 2019, 11, 2251-2268.	0.6	4
347	Hematologic Malignancies. , 2019, , 169-191.		0
348	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
349	Boosting $\gamma\delta$ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. <i>Oncotarget</i> , 2019, 8, 1554175.	2.1	53
350	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , 2019, 9, 370-383.	7.7	380
351	PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. <i>International Immunopharmacology</i> , 2019, 66, 127-138.	1.7	18
352	Recent Advances in Anti-cancer Protein/Peptide Delivery. <i>Bioconjugate Chemistry</i> , 2019, 30, 305-324.	1.8	113
353	Novel treatment approaches and future perspectives in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882051.	1.1	11
354	Therapeutic Targets for Bone and Soft-Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 170.	1.8	52
355	Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 378-398.	2.6	66
356	The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 787-797.	1.3	12

#	ARTICLE	IF	CITATIONS
357	The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1470-1481.	2.0	229
358	Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 101-106.	0.6	7
359	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. <i>Journal of Drug Targeting</i> , 2019, 27, 244-256.	2.1	86
360	The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. <i>Haematologica</i> , 2020, 105, 1593-1603.	1.7	28
361	Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 18-27.	2.0	46
362	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
363	Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 2659-2667.	2.6	15
364	Follicular Lymphoma. , 2020, , .		0
365	Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice. <i>Cancers</i> , 2020, 12, 63.	1.7	36
366	PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma. <i>Pathology Research and Practice</i> , 2020, 216, 153096.	1.0	2
367	Analysis of single-cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e133.	1.7	17
368	An analysis of genetic targets for guiding clinical management of follicular lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 1361-1372.	1.0	0
369	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. <i>Vaccines</i> , 2020, 8, 708.	2.1	13
370	Haploidentical Stem Cell Transplantation in Lymphomas—Expectations and Pitfalls. <i>Journal of Clinical Medicine</i> , 2020, 9, 3589.	1.0	6
371	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. <i>Seminars in Cancer Biology</i> , 2022, 86, 1033-1057.	4.3	14
372	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 36.	1.0	26
373	Immune-Checkpoint Blockade Therapy in Lymphoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5456.	1.8	24
374	Precision medicine in follicular lymphoma: Focus on predictive biomarkers. <i>Hematological Oncology</i> , 2020, 38, 625-639.	0.8	4

#	ARTICLE	IF	CITATIONS
375	Immunosuppressive Property of MSCs Mediated by Cell Surface Receptors. <i>Frontiers in Immunology</i> , 2020, 11, 1076.	2.2	61
376	Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatmentâ€”Current Progress, Strategy, and Future Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 1508.	2.2	60
377	Opium and risk of gastrointestinal cancer: a case-control study. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 697-705.	0.4	4
378	Identification and Screening of Natural Neuraminidase Inhibitors from Reduning Injection via One-Step High-Performance Liquid Chromatography-Fraction Collector and UHPLC/Q-TOF-MS. <i>International Journal of Analytical Chemistry</i> , 2020, 2020, 1-11.	0.4	4
379	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3837.	1.7	9
381	Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	13
382	Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!. <i>Journal of Cellular Physiology</i> , 2020, 235, 9080-9097.	2.0	19
383	Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. <i>Cancer Treatment Reviews</i> , 2020, 88, 102042.	3.4	20
384	Immunotherapy in Hematologic Malignancies. <i>Current Oncology</i> , 2020, 27, 124-131.	0.9	20
385	Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature. <i>Immunotherapy</i> , 2020, 12, 549-554.	1.0	13
386	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. <i>Biomarker Research</i> , 2020, 8, 19.	2.8	42
387	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. <i>Frontiers in Medicine</i> , 2020, 7, 50.	1.2	11
388	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. <i>Blood Reviews</i> , 2020, 44, 100678.	2.8	38
389	The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. <i>Experimental Hematology and Oncology</i> , 2020, 9, 9.	2.0	9
390	Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. <i>Cells</i> , 2020, 9, 1578.	1.8	8
391	Advances in Treatment of Follicular Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 231-240.	1.0	5
392	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 375-392.	1.0	5
393	Cytokines as potential combination agents with PDâ€1/PDâ€L1 blockade for cancer treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 5449-5460.	2.0	42

#	ARTICLE	IF	CITATIONS
394	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52
395	Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. <i>BMC Cancer</i> , 2020, 20, 59.	1.1	8
396	Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-lymphoblastic leukemia, especially in relapse and at diagnosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 336-347.	0.7	10
397	Functional Differences Between EBV- and CMV-specific CD8 ⁺ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL. <i>HemaSphere</i> , 2020, 4, e337.	1.2	3
398	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. <i>Cancer Cell</i> , 2020, 37, 674-689.e12.	7.7	55
399	Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 913-925.	2.0	7
400	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. <i>Blood</i> , 2021, 137, 216-231.	0.6	40
401	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
402	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	0.6	69
403	The Landscape of Checkpoint Inhibition in the Management of Hematological Malignancies. <i>Cancer Research Journal</i> , 2021, 9, 122.	0.0	0
404	Recent advances in cellular therapy for malignant lymphoma. <i>Cytotherapy</i> , 2021, 23, 662-671.	0.3	5
405	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 641.	1.7	7
406	Targeted Treatment of Follicular Lymphoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 152.	1.1	3
407	Checkpoint blockade in FL: eluding the king. <i>Blood</i> , 2021, 137, 581-582.	0.6	0
408	Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3302.	1.8	9
409	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557.	1.8	34
410	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. <i>Blood Reviews</i> , 2021, 50, 100832.	2.8	5
411	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. <i>International Immunopharmacology</i> , 2021, 93, 107403.	1.7	30

#	ARTICLE	IF	CITATIONS
412	Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. <i>European Journal of Haematology</i> , 2021, 107, 81-91.	1.1	6
413	PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. <i>Cells</i> , 2021, 10, 1152.	1.8	12
414	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 883-892.	5.1	116
415	A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. <i>Statistics in Medicine</i> , 2021, 40, 4629-4639.	0.8	0
416	PD-1 and PD-L2: Do they have prognostic value in lymphomas?. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	0
417	Immune checkpoint inhibitors in lymphoma: challenges and opportunities. <i>Annals of Translational Medicine</i> , 2021, 9, 1037-1037.	0.7	30
418	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
419	Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatfrom for Anticancer Drug Delivery. <i>Small</i> , 2021, 17, e2101460.	5.2	87
420	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. <i>International Immunopharmacology</i> , 2021, 98, 107870.	1.7	13
421	Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review. <i>Cancer Biology and Therapy</i> , 2021, , 1-7.	1.5	2
422	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. <i>Cancers</i> , 2021, 13, 284.	1.7	15
423	Immuno-Oncology in the Era of Personalized Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 117-129.	0.8	4
424	Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492097636.	0.6	6
425	New Targeted Therapies for Indolent B-Cell Malignancies in Older Patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e365-e374.	1.8	2
426	PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. <i>Oncotarget</i> , 2016, 7, 59976-59986.	0.8	56
427	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. <i>Oncotarget</i> , 2016, 7, 76902-76919.	0.8	131
428	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 59901-59914.	0.8	64
429	Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. <i>Oncotarget</i> , 2017, 8, 89391-89405.	0.8	25

#	ARTICLE	IF	CITATIONS
430	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	0.8	61
431	Scientific rationale for immunotherapy in lymphoma and predictors of response. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	2
432	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy-free Era. <i>Current Medicinal Chemistry</i> , 2019, 26, 1002-1018.	1.2	11
433	The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials. <i>Current Drug Targets</i> , 2020, 21, 1733-1751.	1.0	6
434	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. , 2017, 37, 5655-5666.		26
436	Immune Checkpoint Blockers and Ovarian Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 182-189.	0.1	4
437	Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia. <i>African Health Sciences</i> , 2020, 20, 1264-1272.	0.3	15
438	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021, 16, 761-771.	1.7	5
439	Targeted Therapy in Lymphoproliferative Disorders (Excluding CAR T Cells). , 2015, 12, .		0
440	Recently Developed Therapeutic Agents for B-cell Non-Hodgkin Lymphoma. <i>Korean Journal of Medicine</i> , 2015, 88, 247.	0.1	0
441	Anti-TIM-3 Antibody Prevents Lymphocyte Apoptosis and Enhances Dendritic Cell Cancer Therapy. <i>The Showa University Journal of Medical Sciences</i> , 2015, 27, 1-9.	0.1	0
442	Advances in Immunotherapy for Hematological Malignancies. <i>Journal of the Nihon University Medical Association</i> , 2016, 75, 167-170.	0.0	0
443	Promising Immunotherapeutic Approaches in Clinical Trials. , 2016, , 351-416.		1
444	Responses and response evaluation of immune checkpoint inhibitors in lymphoma. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	0
445	Follicular lymphoma. , 2017, , 75-96.		0
446	Immune Checkpoint Inhibitors in the Treatment of Lymphomas. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018, 11, 303-312.	0.1	10
447	Gastrointestinal Lymphomas. , 2019, , 960-969.		0
448	Anticancer Immunotherapy: Prospects and Challenges. , 2019, , 189-228.		0

#	ARTICLE	IF	CITATIONS
449	Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy. <i>Journal of Immunological Sciences</i> , 2019, 3, 9-12.	0.5	1
450	Targeting the Tumor Microenvironment. , 2020, , 219-231.		0
451	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2020, , 159-212.		0
452	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
453	Therapy Response Imaging in Lymphoma and Hematologic Malignancies. <i>Medical Radiology</i> , 2020, , 177-200.	0.0	0
454	The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. <i>Anticancer Research</i> , 2020, 40, 1141-1146.	0.5	3
456	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. <i>ChemistrySelect</i> , 2022, 7, 833-866.	0.7	0
461	Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines and. <i>American Journal of Cancer Research</i> , 2020, 10, 2800-2812.	1.4	4
462	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 273-295.	0.8	1
463	CD300a Receptor Blocking Enhances Early Clearance of <i>Leishmania donovani</i> From Its Mammalian Host Through Modulation of Effector Functions of Phagocytic and Antigen Experienced T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 793611.	2.2	7
465	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 1143-1151.	2.5	21
466	Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1257.	1.0	5
467	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. <i>Seminars in Cancer Biology</i> , 2022, 86, 607-623.	4.3	10
468	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	0.6	8
469	Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 84-94.	0.3	0
470	Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment. <i>Frontiers in Pharmacology</i> , 2022, 13, 774440.	1.6	5
479	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 2736-2745.	2.0	8
483	Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma. <i>Cancers</i> , 2022, 14, 2158.	1.7	3

#	ARTICLE	IF	CITATIONS
484	Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8 ⁺ T-cells despite immune checkpoint signaling. <i>Blood Research</i> , 2022, , .	0.5	3
485	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	1.7	29
487	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <sc>FUSION NHL</sc> 001 trial. <i>Cancer Reports</i> , 2023, 6, .	0.6	6
488	Immunohistochemical Expression of Programmed Death Ligand 1 in Oral Extranodal Diffuse Large B Cell Lymphoma. <i>European Journal of Dentistry</i> , 0, , .	0.8	0
489	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114505.	6.6	15
491	Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 704.	0.3	3
492	Chicken-derived <sc>CD20</sc> antibodies with potent B-cell depletion activity. <i>British Journal of Haematology</i> , 2022, 199, 560-571.	1.2	2
493	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. <i>ACS Central Science</i> , 2022, 8, 1299-1305.	5.3	8
494	Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. <i>RMD Open</i> , 2022, 8, e002612.	1.8	6
495	Immunotherapy for the treatment of pediatric brain tumors: a narrative review. <i>Translational Pediatrics</i> , 2022, 11, 2040-2056.	0.5	2
496	Early Increase of Circulating Transitional B Cells and Autoantibodies to <sc>Joint-Related</sc> Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor-Induced Inflammatory Arthritis. <i>Arthritis and Rheumatology</i> , 2023, 75, 856-863.	2.9	3
497	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2022, 7, 100646.	2.0	7
498	Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. <i>Medicine (United States)</i> , 2022, 101, e32333.	0.4	5
499	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. <i>European Medical Journal Oncology</i> , 0, , 70-76.	0.0	1
500	A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?. <i>Translational Oncology</i> , 2023, 30, 101636.	1.7	2
501	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0
502	Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review. <i>Current Cancer Therapy Reviews</i> , 2024, 20, 53-99.	0.2	0
504	Novel technologies for applying immune checkpoint blockers. <i>International Review of Cell and Molecular Biology</i> , 2024, , 1-101.	1.6	2

#	ARTICLE	IF	CITATIONS
505	The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2+ /HER-breast cancer cells. , 2023, 40, .		2
511	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5